Merck & Co., Inc. $MRK Shares Sold by Advisors Management Group Inc. ADV

Advisors Management Group Inc. ADV decreased its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 15.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 58,625 shares of the company’s stock after selling 10,482 shares during the quarter. Merck & Co., Inc. comprises 1.1% of Advisors Management Group Inc. ADV’s holdings, making the stock its 25th biggest position. Advisors Management Group Inc. ADV’s holdings in Merck & Co., Inc. were worth $6,171,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. DLD Asset Management LP increased its position in shares of Merck & Co., Inc. by 30.1% in the 3rd quarter. DLD Asset Management LP now owns 47,500,000 shares of the company’s stock valued at $3,986,675,000 after acquiring an additional 11,000,000 shares during the period. Fisher Asset Management LLC lifted its position in Merck & Co., Inc. by 2.3% during the 2nd quarter. Fisher Asset Management LLC now owns 25,013,697 shares of the company’s stock worth $1,980,084,000 after acquiring an additional 567,900 shares during the period. Legal & General Group Plc grew its stake in Merck & Co., Inc. by 5.9% during the 3rd quarter. Legal & General Group Plc now owns 20,659,157 shares of the company’s stock valued at $1,733,923,000 after purchasing an additional 1,156,112 shares during the last quarter. Invesco Ltd. raised its stake in shares of Merck & Co., Inc. by 16.6% in the third quarter. Invesco Ltd. now owns 19,844,936 shares of the company’s stock worth $1,665,585,000 after purchasing an additional 2,821,766 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership lifted its holdings in shares of Merck & Co., Inc. by 35.5% during the second quarter. Arrowstreet Capital Limited Partnership now owns 19,456,096 shares of the company’s stock worth $1,540,145,000 after purchasing an additional 5,094,088 shares during the period. Hedge funds and other institutional investors own 76.07% of the company’s stock.

More Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck announced a US$6.7B acquisition of Terns Pharmaceuticals to add TERN-701 (an investigational oral CML therapy) to its oncology/hematology pipeline—a clear move to build revenue and R&D options ahead of Keytruda’s planned 2028 exclusivity loss. Merck Targets Post Keytruda Future With US$6.7b Terns Acquisition
• Positive Sentiment: RBC reiterated an Outperform and kept a $142 price target after Merck’s Terns call, signaling sell‑side support for the strategy despite questions about the transaction premium. RBC Reiterates Merck (MRK) Outperform
• Positive Sentiment: Agilent won FDA approval for the PD‑L1 22C3 companion diagnostic in esophageal/GEJ carcinoma, which can help identify patients for Keytruda treatment—supportive for near‑term uptake in that indication. Agilent receives FDA approval for PD-L1 1HC 22C3 pharmDx
• Positive Sentiment: High-profile bullish commentary (e.g., Jim Cramer) and option/trade ideas targeting MRK indicate elevated investor interest and constructive conviction in Merck as a defensive large‑cap pharma. Jim Cramer on Merck & Co.
• Neutral Sentiment: Analyst model tweaks are minor: Erste marginally raised FY2026 EPS estimates (from $5.12 to $5.13), reflecting limited near‑term changes to consensus earnings expectations. MarketBeat analyst update
• Neutral Sentiment: Coverage pieces note Merck has outperformed recently (stock up ~50% over six months); some articles offer tactical trade ideas (options/covered calls) that reflect market momentum rather than fundamental shifts. Merck Stock Soars 50% in 6 Months
• Negative Sentiment: Keytruda’s planned 2028 loss of exclusivity remains the central long‑term risk—analysts and articles stress patent cliff exposure and some weak vaccine sales, which temper valuation upside. Zacks: Merck Stock Soars 50% in 6 Months
• Negative Sentiment: The proposed Terns transaction may face rival interest and is the subject of a shareholder‑lawyer investigation (Kahn Swick & Foti), introducing deal execution, regulatory and legal risk that could delay or change terms. MSN: Merck’s Terns acquisition may face rival interest BusinessWire: KSF Investigation

Merck & Co., Inc. Trading Up 0.7%

Shares of MRK stock opened at $119.77 on Friday. Merck & Co., Inc. has a 1-year low of $73.31 and a 1-year high of $125.14. The company has a market cap of $296.13 billion, a price-to-earnings ratio of 16.45, a PEG ratio of 2.31 and a beta of 0.27. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.54 and a quick ratio of 1.30. The stock has a 50 day simple moving average of $116.65 and a 200-day simple moving average of $101.93.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings results on Tuesday, February 3rd. The company reported $2.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.01 by $0.03. The firm had revenue of $16.40 billion for the quarter, compared to analysts’ expectations of $16.19 billion. Merck & Co., Inc. had a net margin of 28.08% and a return on equity of 44.57%. The firm’s revenue for the quarter was up 5.0% compared to the same quarter last year. During the same quarter last year, the company earned $1.72 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. On average, equities research analysts expect that Merck & Co., Inc. will post 9.01 EPS for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, April 7th. Stockholders of record on Monday, March 16th will be paid a dividend of $0.85 per share. The ex-dividend date of this dividend is Monday, March 16th. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.8%. Merck & Co., Inc.’s payout ratio is currently 46.70%.

Analyst Ratings Changes

Several brokerages recently weighed in on MRK. Guggenheim increased their price target on shares of Merck & Co., Inc. from $122.00 to $140.00 and gave the stock a “buy” rating in a report on Friday, February 6th. Wells Fargo & Company increased their price objective on shares of Merck & Co., Inc. from $135.00 to $150.00 and gave the stock an “overweight” rating in a research note on Thursday, March 12th. TD Cowen boosted their target price on shares of Merck & Co., Inc. from $100.00 to $120.00 and gave the company a “hold” rating in a research report on Tuesday, January 20th. Barclays assumed coverage on shares of Merck & Co., Inc. in a report on Friday, February 20th. They issued an “overweight” rating and a $140.00 price target on the stock. Finally, Zacks Research upgraded Merck & Co., Inc. from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 17th. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and seven have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $127.13.

Insider Buying and Selling at Merck & Co., Inc.

In other news, EVP Richard R. Deluca sold 37,685 shares of the firm’s stock in a transaction that occurred on Friday, February 6th. The stock was sold at an average price of $120.92, for a total value of $4,556,870.20. Following the transaction, the executive vice president owned 160,174 shares in the company, valued at $19,368,240.08. This trade represents a 19.05% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP David Michael Williams sold 5,000 shares of Merck & Co., Inc. stock in a transaction that occurred on Friday, February 6th. The stock was sold at an average price of $121.91, for a total value of $609,550.00. Following the completion of the sale, the executive vice president directly owned 30,838 shares in the company, valued at $3,759,460.58. This represents a 13.95% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 320,176 shares of company stock valued at $38,281,735. Corporate insiders own 0.13% of the company’s stock.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.